Niva Bupa Health Insurance Company Ltd (NIVABUPA) Q1 FY27 Results Analysis: PAT Nearly Doubles, Combined Ratio Improves 495 bps
Niva Bupa Health Insurance Company Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,273.72 Cr (+28.56% YoY) and PAT growth of +92.89% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 2,273.72 Cr (+28.56% YoY) |
| PAT (Q1) | Rs. 137.80 Cr (+92.89% YoY) |
| EPS (Q1) | Rs. 0.75 (+92.31% YoY) |
| Market cap | Rs. 15,888.62 Cr |
| CMP | Rs. 85.92 |
Quarter Snapshot
NIVABUPA delivered a strong Q1 FY27 with 28.6% revenue growth and PAT nearly doubling, driven by a 495 bps improvement in combined ratio to 93.55%. The health segment remains the core driver with expanding margins. However, a declining solvency ratio and pending regulatory forbearance on EOM exceedance are key risks to monitor.
Key Investment Insights
Key Positives
- Insurance Revenue grew 28.6% YoY to Rs.2,273.72 Cr, well above industry CAGR of 17-19%.
- Combined Operating Ratio improved to 93.55% from 98.50% YoY, a 495 bps improvement.
- PAT nearly doubled YoY to Rs.137.80 Cr, a 92.9% increase.
- Claims ratio improved to 63.01% from 66.83% YoY.
- Expense ratio improved to 30.54% from 31.67% YoY.
- Health segment revenue grew 28.44% YoY with profit up 93%.
- No exceptional items; reported PAT is normalized.
Risk Factors
- Solvency ratio declined to 2.25x from 2.86x YoY and 2.49x QoQ, requiring monitoring.
- Travel segment reported a small loss of Rs.0.29 Cr.
- EOM ratio at 35.15% is near the cap of 36.24% (including allowances); FY25 forbearance still pending.
- Contingent liability of Rs.12,716 lakhs for income tax demands (AY2020-21 to AY2023-24).
- Auditor's Emphasis of Matter on pending EOM exceedance forbearance.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.